Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) were down 1.6% on Monday . The stock traded as low as $4.99 and last traded at $5.04, with a volume of 467,522 shares trading hands. The stock had previously closed at $5.12.

Several analysts have weighed in on ZIOP shares. Griffin Securities reiterated a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research note on Friday, July 1st. Vetr downgraded Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price target on the stock. in a research note on Monday, April 18th. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Wednesday, July 27th. Raymond James Financial Inc. started coverage on Ziopharm Oncology in a research note on Thursday, June 2nd. They set a “market perform” rating on the stock. Finally, Mizuho boosted their price target on Ziopharm Oncology from $6.00 to $7.00 and gave the company a “neutral” rating in a research note on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Ziopharm Oncology has an average rating of “Hold” and a consensus price target of $9.55.

The firm has a 50-day moving average price of $5.35 and a 200-day moving average price of $6.76. The firm’s market capitalization is $634.15 million.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.01. The business earned $1.97 million during the quarter, compared to the consensus estimate of $1.89 million. Ziopharm Oncology’s quarterly revenue was up 623.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.69) EPS. Equities analysts forecast that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current fiscal year.

A number of hedge funds have bought and sold shares of the stock. California State Teachers Retirement System boosted its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares in the last quarter. Swiss National Bank boosted its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the period. California Public Employees Retirement System boosted its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the period. Finally, Morgan Stanley boosted its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.